Molecular Diagnosis of Clostridium Difficile Market

Clostridium difficile infection (CDI) is one of the most important causes of nosocomial diarrhoea and is also becoming important in the community and in populations with low or no risk factors.Especially during outbreaks and during the spread of strains with increased virulence it is important that the laboratory diagnosis is rapid and sensitive to ensure appropriate therapy and quick implementation of hospital hygiene measures.Therefore, the improvement of diagnostic methods is becoming more and more important.

Molecular Diagnosis of Clostridium Difficile Market contains market size and forecasts of Molecular Diagnosis of Clostridium Difficile in global, including the following market information:

Global Molecular Diagnosis of Clostridium Difficile Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Molecular Diagnosis of Clostridium Difficile Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Molecular Diagnosis of Clostridium Difficile companies in 2021 (%)

The global Molecular Diagnosis of Clostridium Difficile market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Sensitivity Above 90% Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Molecular Diagnosis of Clostridium Difficile include Roche, Thermo Scientific, Cepheid (Danaher), BD, Meridian, TECHLAB, Luminex, CerTest Biotec and Quidel, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Molecular Diagnosis of Clostridium Difficile manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Molecular Diagnosis of Clostridium Difficile Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Molecular Diagnosis of Clostridium Difficile Market Segment Percentages, by Type, 2021 (%)

Sensitivity Above 90%

Sensitivity Below 90%

Global Molecular Diagnosis of Clostridium Difficile Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Molecular Diagnosis of Clostridium Difficile Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Laboratory

Home Care

Others

Global Molecular Diagnosis of Clostridium Difficile Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Molecular Diagnosis of Clostridium Difficile Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Molecular Diagnosis of Clostridium Difficile revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Molecular Diagnosis of Clostridium Difficile revenues share in global market, 2021 (%)

Key companies Molecular Diagnosis of Clostridium Difficile sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Molecular Diagnosis of Clostridium Difficile sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Roche

Thermo Scientific

Cepheid (Danaher)

BD

Meridian

TECHLAB

Luminex

CerTest Biotec

Quidel

Zhejiang Orient Gene Biotech

Beijing Promed Medical Technology

Jiangsu Besthree Biotechnology